author-photo

Sharon Karan

Vertex Pharmaceuticals

3

Papers

50

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792).

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (25)
Abstract CT012: Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792):

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (10)
Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (15)